Glucoryl MV 1/0.3 mg Tablet

Glucoryl MV 1/0.3 mg Tablet is an anti-diabetic medicine. It is a combination of Glimepiride (1mg), Metformin (500mg) and Voglibose (0.3mg). It is prescribed to treat type 2 diabetes mellitus in adults. It works by controlling blood sugar levels in people with diabetes. It should be taken with food at the same time each day to get effective results. Don't take more than the recommended dose

• Type 2 diabetes mellitus

Glucoryl MV 1/0.3 mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Nausea
• Diarrhea
• Abdominal pain
• Hypoglycemia (low blood glucose level)
• Loss of appetite

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Glucoryl MV 1/0.3 mg Tablet in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.
  
  

• Glucoryl MV 1/0.3 mg Tablet is an anti-diabetic medicine. It is a combination of Glimepiride (1mg), Metformin (500mg) and Voglibose (0.3mg). As a sulfonylurea, glimepiride minimizes blood sugar by stimulating the pancreas to secrete more insulin.
• Metformin is a biguanide that increases the body's tolerance to insulin, reduces the liver's synthesis of glucose, and slows down the intestines' absorption of glucose.
• Alpha-glucosidase inhibitors like voglibose prevent complex sugars from breaking down into simple sugars like glucose. As a result, this medicine prevents blood glucose levels from rising to extremely high levels immediately after meals.
  
  

• Sharma, S., Tandon, V. R., & Mahajan, A. (2016). Prescribing pattern of oral antihyperglycaemic drugs, rationality and adherence to American Diabetes Association (ADA) treatment guidelines among type 2 diabetes mellitus (T2DM) postmenopausal women. Journal of Clinical and Diagnostic Research: JCDR, 10(1), OC11. https://pubmed.ncbi.nlm.nih.gov/26894107/
• Joyson, B. S., Jacob, M. S., Mathew, F., Thomas, J., & Sushilkumar, P. L. (2019). IDENTIFICATION, ASSESSMENT AND ANALYSING THE COST EFFECTIVENESS OF ORAL HYPOGLYCEMIC AGENTS FOR PHARMACOECONOMIC EVALUATION IN A TERTIARY CARE TEACHING HOSPITAL. World J Pharm Res, 8(12), 1229-42.
• Yogish, G. M. (2013). Efficacy and Safety of Voglibose Versus Acarbose as Add on Therapy to Metformin and Sulfonlyurea in Type 2 Diabetes Mellitus-a Comparative Randomized Controlled Study (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).
• Suman, S. V. (2020). Efficacy and Safety of Voglibose Vs Glimepride in Combination with Metformin in Type 2 Diabetes: A randomized Controlled Trial (Doctoral dissertation).
• BANTWAL, G., AYYAR, V., KOVIL, R., CHAWLA, M., SHAH, T., KUMAR, S. ... & REVANKAR, S. (2021). Assessment of Clinical Experience of Triple Drug Fixed-dose Combination of Glimepiride, Metformin and Voglibose in the Management of Type 2 Diabetes Mellitus: A Retrospective Study. Journal of Clinical & Diagnostic Research, 15(9).